Trom Industries Limited Receives Purchase Order from Captalo Pharma Private Limited
Trom Industries Limited announced on March 23, 2026, that it has received a purchase order from Captalo Pharma Private Limited. The order is for the supply and design, installation, testing, and commissioning of a 125 KW grid interactive solar power plant.The value of the order is INR 34,43,962.50 inclusive of goods and services tax. The project is expected to be completed within one year.
According to information provided, the order is from a domestic entity, and neither the promoter group nor group companies have any interest in Captalo Pharma Private Limited. The order does not constitute a related party transaction.
Here's a summary of the key details of the purchase order:
| Sr. No. | Particulars | Details |
|---|---|---|
| 1 | Name(s) of parties with whom order is received | M/s. Captalo Pharma Private Limited |
| 2 | Significant terms and conditions of order(s)/contract(s) awarded in brief | Supply and Design, Installation, Testing, Commissioning of Solar Photovoltic (SPV) Based grid Interactive 125KW Solar Power Plant. |
| 3 | Whether order(s)/contract(s) have been awarded by domestic/ international entity | Domestic Entity |
| 4 | Nature of order(s) /contract(s) | Supply of Solar Photovoltic (SPV) Based grid interactive 125 KW Solar Power Plant along with Design, Installation, Testing, Commissioning of it. |
| 5 | Whether domestic or international | Domestic Order |
| 6 | Time period by which the order(s)/contract(s) is to be executed | To be completed within a year |
| 7 | Broad consideration or size of the order(s)/contract(s) | Order worth value of INR 34,43,962.50/- inclusive GST |
| 8 | Whether the promoter/promoter group/group companies have any interest in the entity that awarded the order(s)/contract(s)? If yes, nature of interest and details thereof | No |
| 9 | Whether the order(s)/contract(s) would fall within related party transactions? If y e s , w h e t h e r the same is done at 'arm's length'. | No |
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.